190 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by Millstone Evans Group LLC

Millstone Evans Group LLC bought a new position in shares of United Therapeutics Co. (NASDAQ:UTHR) in the 4th quarter, Holdings Channel.com reports. The fund bought 190 shares of the biotechnology company’s stock, valued at approximately $67,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of UTHR. Wealthfront Advisers LLC grew its stake in United Therapeutics by 2,090,573.5% during the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company’s stock worth $6,462,018,000 after purchasing an additional 18,313,424 shares in the last quarter. World Investment Advisors LLC acquired a new position in shares of United Therapeutics during the 3rd quarter worth about $139,206,000. FMR LLC boosted its position in shares of United Therapeutics by 41.1% during the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after acquiring an additional 314,004 shares in the last quarter. Thrivent Financial for Lutherans boosted its position in shares of United Therapeutics by 1,325.5% during the 4th quarter. Thrivent Financial for Lutherans now owns 204,299 shares of the biotechnology company’s stock worth $72,085,000 after acquiring an additional 189,967 shares in the last quarter. Finally, AustralianSuper Pty Ltd boosted its position in shares of United Therapeutics by 577.1% during the 4th quarter. AustralianSuper Pty Ltd now owns 189,780 shares of the biotechnology company’s stock worth $66,962,000 after acquiring an additional 161,751 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. UBS Group upped their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $425.00 price objective on shares of United Therapeutics in a research report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $388.25.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $356.68, for a total transaction of $3,566,800.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $919,164.36. This represents a 79.51 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Nilda Mesa sold 255 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $355.77, for a total value of $90,721.35. Following the sale, the director now directly owns 5,528 shares of the company’s stock, valued at approximately $1,966,696.56. This represents a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 80,255 shares of company stock valued at $28,995,021 in the last ninety days. Insiders own 11.90% of the company’s stock.

United Therapeutics Stock Down 0.2 %

Shares of NASDAQ UTHR opened at $312.99 on Monday. The stock has a market cap of $14.06 billion, a PE ratio of 13.75, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a 52-week low of $221.53 and a 52-week high of $417.82. The business has a 50-day moving average price of $345.10 and a 200 day moving average price of $357.05.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the prior year, the business earned $4.36 EPS. Sell-side analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.